Evidence map›Paper›PMID 39937014›Full record

ReviewCells2025

The Importance of Monitoring Antigen-Specific Memory B Cells, and How ImmunoSpot Assays Are Suitable for This Task.

Greg A Kirchenbaum, Graham Pawelec, Paul V Lehmann

Abstract readReview
In one paragraph

Review in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Extending ImmunoSpotVaccines · 2026
    Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Greg A KirchenbaumResearch and Development, Cellular Technology Ltd. (CTL), Shaker Heights, OH 44122, USA.ORCID 0000-0001-6463-7623
Graham PawelecDepartment of Immunology, University of Tübingen, D-72076 Tübingen, Germany.ORCID 0000-0002-3600-0163
Paul V LehmannResearch and Development, Cellular Technology Ltd. (CTL), Shaker Heights, OH 44122, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Determining an individual's humoral immune reactivity to a pathogen, autoantigen, or environmental agent is traditionally accomplished through the assessment of specific antibody levels in blood. However, in many instances, titers of specific antibodies decline over time and thus do not faithfully reveal prior antigen exposure or establishment of immunological memory. To estimate an individual's humoral immune competence, it is therefore necessary to assess functional B cell memory. Here, we describe novel B cell ELISPOT and FluoroSpot assays (collectively referred to as ImmunoSpot) that can be rapidly developed and validated to characterize the memory B cell (B

Indexed as

AntigensB-LymphocytesEnzyme-Linked Immunospot AssayImmunologic MemoryMemory B CellsAnimalsHumansAntigensaffinity maturationcross reactivityELISPOTFluoroSpothigh throughputIg classimmune monitoringSARS-CoV-2

Identifiers

PMID39937014
PMCPMC11816810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.